GSK doubles down on oncology with $10.6bn Nuvalent takeover - Pharmaceutical Technology

Nuvalent’s two late-stage lung cancer assets – zidesamtinib and neladalkib – are currently under FDA review Nuvalent’s two late-stage lung cancer assets – zidesamtinib and neladalkib – are currently under FDA review. The deal is the largest pure-play acquisition in GSK’s history. MAXSHOT.PL/Shutterstock.com. GSK will acquire lung cancer biotech Nuvalent for $10.6bn in one of its largest ever deals, bolstering its pipeline with two late-stage assets the drugmaker believes have “multi-blockbuster potential”. The all-cash transaction sees GSK pay $124 per share of Nuvalent, representing a 40% premium to the US-listed biotech’s last closing price of $88.49. The British drugmaker will…

Source: Pharmaceutical Technology